And Initiation of Additional Phase 2a Dose
Lyon, France – December 21st, 2021
Osivax, a biopharmaceutical company focused on preventing the spread of constantly mutating global infectious diseases, including influenza and coronaviruses, announced today promising results of its Phase 2a clinical trial with OVX836, Osivax’ broad-spectrum influenza vaccine candidate developed using the company’s proprietary oligoDOM® nanoparticle technology platform. Unlike conventional vaccines which target highly mutating surface proteins and need to be updated to match seasonal influenza strains, OVX836 targets the internal nucleoprotein (NP), a highly conserved antigen that is far less susceptible to mutations and would thus provide universal protection.